RNS Number : 7028F
OptiBiotix Health PLC
26 September 2024

OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the Group")

ProBiotix Health plc - response to requisition notice

OptiBiotix Health plc ("OptiBiotix") notes the announcement made by ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, on 25 September 2024, that it has received a notice requisitioning a General Meeting (the "**Requisition Notice**") which has been served by Platform Securities Nominees Limited, on behalf of Seneca Partners.

OptiBiotix is aware of the Requisition Notice and of the detailed reasons given by Seneca Partners for resorting to this course of action.

OptiBiotix intends to vote its holding of 53,533,333 ordinary shares in support of the resolutions proposed by Seneca Partners and will publish its full reasons for supporting the proposals put forward by Seneca Partners in due course.

In the meantime, OptiBiotix believes that it is important that ProBiotix Health plc clarify its issued share capital which is stated to be 158,166,666 shares carrying voting rights in its announcement of 4 September 2024 but is stated to be 121,666,666 shares carrying voting rights on its website at https://probiotixhealth-ir.com/share-information/shareholder-information.

Neil Davidson, Chairman of OptiBiotix Health plc said: *"I am sure that Seneca Partners have only taken this action as an institutional shareholder after much careful consideration and for good reason. Shareholder activism led by institutional shareholders is an important aspect of corporate governance and should generally be seen as an indication that serious failings have been identified which need to be addressed in the best interests of all shareholders."*

For further information, please contact: OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman — *Contact via Walbrook below*
Stephen O'Hara, Chief Executive

Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti

Peterhouse Capital Limited (Broker) Tel: 020 7220 9797
Duncan Vasey / Lucy Williams

Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RSPFLFITADIEFIS